With our partner Salesforce, unify sales, marketing and customer service. Accele your growth!
Wandercraft, a pioneer of functional assistance robotics, announces the launch of a clinical trial for its Personal Exoskeletonfirst self-balanced exoskeleton designed for personal use. This study, conducted in the United States, aims to assess the efficiency and safety of the device for people with spinal cord damage (SCI).
The test will take place at James J. Peters goes Medical Center in New York and Kessler Institute for Rehabilitation in New Jersey. It concerns adult patients with complete or incomplete SCIs in terms of T6 or higher. The objective is to demonstrate that the exoskeleton allows an autonomous walk without recourse to crutches, a major innovation in the field of mobility medicalization.
We could not confirm your registration.
Your registration is confirmed.
“We have already observed the impact of our exoskeletons in rehabilitation centers. This clinical trial is an essential step to demonstrate the contribution of the personal exoskeleton to the autonomy of walking, ” Matthieu Masin, CEO of Wandercraft. By integrating a dynamic rebalancing technology, the exoskeleton allows a fluid approach on various types of surfaces, including carpets and irregular floors.
The SCIs affect approximately 294,000 people in the United Stateswith almost 17,810 new cases each year. This pathology alters the motor and autonomic functions of the body, impacting breathing, heart regulation and mobility. The absence of curative treatment reinforces the need for technological alternatives to restore functional autonomy.
Wandercraft, already recognized for theAtalanting Xan exoskeleton used in rehabilitation, takes a new step with this personal device. The company intends to open up prospects for home marketing, a strategy that could transform the daily life of its users.
Founded in 2012 in Paris, Wandercraft is directed by Matthieu Masin and raised more than $ 102.8 million with investors such as Bpifrance, Quadrant Management and European Investment Bank as lead investor. The company is positioned in front of competitors such as Rewalk Robotics And Ekso Bionicswhich also develop exoskeleton solutions but with different approaches in terms of stabilization and user autonomy.
